Skip to main content
Log in

Synthesis, Crystal Structure and Cytotoxic Properties of Nitrocombretastatins (E)- and (Z)-5-(4-Methoxy-3-nitrostyryl)-1,2,3-trimethoxybenzene

  • Original Paper
  • Published:
Journal of Chemical Crystallography Aims and scope Submit manuscript

Abstract

(Z)-5-(4-Methoxy-3-nitrostyryl)-1,2,3-trimethoxybenzene (2) is the key intermediate for the preparation of several anticancer agents, belonging to the group of aminocombretastatins (AC7739, AVE8062). Synthesis of the title compounds was achieved by a modified Wittig reaction under Boden’s conditions using potassium carbonate as a base and 18-crown-6 as a phase transfer catalyst. Both π-diastereoisomers were characterized by single crystal X-ray diffraction analysis, 1H and 13C NMR spectroscopy. (E)-5-(4-Methoxy-3-nitrostyryl)-1,2,3-trimethoxybenzene (1) crystallizes in the orthorhombic space group Pbca (N° 61) with one molecule per asymmetric unit while (Z)-5-(4-methoxy-3-nitrostyryl)-1,2,3-trimethoxybenzene (2) crystallizes in the monoclinic space group P21/c (N° 14) also with one molecule per asymmetric unit. In both compounds no typical hydrogen bonding interactions could be located. The three-dimensional crystal structure is stabilized by C–H···O interactions. The cytotoxicity of synthesized nitrocombretastatins was also evaluated. The Z-stilbene 2 inhibited cell growth with IC50 of 0.15 and 0.11 µM following 72 h treatment in EA.hy926 and MG-63 cell lines.

Graphical Abstract

Synthesis, crystal structure and cytotoxic properties of two stilbene derivatives (E)- and (Z)-5-(4-methoxy-3-nitrostyryl)-1,2,3-trimethoxybenzene are reported. The compounds can be examined as precursors for the synthesis of combretastatin A-4 analogues.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Chart 1
Scheme 1
Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Wolter F, Stein J (2002) Drugs Future 27:949

    Article  CAS  Google Scholar 

  2. Piotrowska H, Kucinska M, Murias M (2012) Mut Res 750:60

    Article  CAS  Google Scholar 

  3. Estrela JM, Ortega A, Mena S, Rodriguez ML, Asensi M (2013) Crit Rev Clin Lab Sci 50:65

    Article  CAS  Google Scholar 

  4. Tron GC, Pirali T, Sorba G, Pagliai F, Busacca S, Genazzani AA (2006) J Med Chem 49:3033

    Article  CAS  Google Scholar 

  5. Pettit GR, Singh SB, Boyd MR, Hamel E, Pettit RK, Schmidt JM, Hogan F (1995) J Med Chem 38:1666

    Article  CAS  Google Scholar 

  6. McGown AT, Fox BW (1990) Cancer Chemother Pharmacol 26:79

    Article  CAS  Google Scholar 

  7. Nam H-X (2003) Curr Med Chem 10:1697

    Article  CAS  Google Scholar 

  8. Cirla A, Mann J (2003) Nat Prod Rep 20:558

    Article  CAS  Google Scholar 

  9. Hsieh HP, Liou JP, Mahindroo N (2005) Curr Pharmaceut Design 11:1655

    Article  CAS  Google Scholar 

  10. Chaudhary A, Pandeya SN, Kumar P, Sharma PP, Gupta S, Soni N, Verma KK, Bhardwaj G (2007) Mini-Rev Med Chem 7:1186

    Article  CAS  Google Scholar 

  11. Singh R, Kaur H (2009) Synthesis 2009:2471

    Article  Google Scholar 

  12. Ohsumi K, Nakagawa R, Fukuda Y, Hatanaka T, Morinaga Y, Nihei Y, Ohishi K, Suga Y, Akiyama Y, Tsuji T (1998) J Med Chem 41:3022

    Article  CAS  Google Scholar 

  13. Ohsumi K, Hatanaka T, Nakagawa R, Fukuda Y, Morinaga Y, Suga Y, Nihei Y, Ohishi K, Akiyama Y, Tsuji T (1999) Anticancer Drug Des 14:539

    CAS  Google Scholar 

  14. Delmonte A, Sessa C (2009) Expert Opin Investig Drugs 18:1541

    Article  CAS  Google Scholar 

  15. Mita MM, Sargsyan L, Mita AC, Spar M (2013) Expert Opin Investig Drugs 22:317

    Article  CAS  Google Scholar 

  16. Pinney KG, Mejia MP, Villalobos VM, Rosenquist BE, Pettit GR, Verdier-Pinard P, Hamel E (2000) Bioorg Med Chem 8:2417

    Article  CAS  Google Scholar 

  17. Kamal A, Shaik B, Nayak VL, Nagaraju B, Kapure JS, Malik MS, Shaik TB, Prasad B (2014) Bioorg Med Chem 22:5155

    Article  CAS  Google Scholar 

  18. Coccetti P, Montano G, Lombardo A, Tripodi F, Orsini F, Pagliarin R (2010) Bioorg Med Chem Lett 20:2780

    Article  CAS  Google Scholar 

  19. Boden R (1975) Synthesis 1975:784

    Article  Google Scholar 

  20. Lara-Ochoa F, Espinosa-Pérez G (2007) Tetrahedron Lett 48:7007

    Article  CAS  Google Scholar 

  21. Mosmann T (1983) J Immunol Methods 65:55

    Article  CAS  Google Scholar 

  22. Pettit GR, Singh SB, Niven ML, Hamel E, Schmidt JM (1987) J Nat Prod 50:119

    Article  CAS  Google Scholar 

  23. CrysAlis PRO (2011) Agilent Technologies. UK Ltd, Yarnton, England

    Google Scholar 

  24. Sheldrick GM (2008) Acta Cryst A 64:112

    Article  CAS  Google Scholar 

  25. Farrugia L (2012) J Appl Crystallogr 45:849

    Article  CAS  Google Scholar 

  26. Macrae CF, Bruno IJ, Chisholm JA, Edgington PR, McCabe P, Pidcock E, Rodriguez-Monge L, Taylor R, van de Streek J, Wood PA (2008) J Appl Cryst 41:466

    Article  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by the Sofia University Scientific Research Fund (Grant 24/2014) and by the Ministry of Education and Science of Bulgaria (Grant DRNF02/1).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ognyan I. Petrov.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gerova, M.S., Encheva, G.R., Nikolova, R.P. et al. Synthesis, Crystal Structure and Cytotoxic Properties of Nitrocombretastatins (E)- and (Z)-5-(4-Methoxy-3-nitrostyryl)-1,2,3-trimethoxybenzene. J Chem Crystallogr 46, 105–112 (2016). https://doi.org/10.1007/s10870-016-0633-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10870-016-0633-3

Keywords

Navigation